AR117219A1 - Formulaciones en cápsulas, método de preparación - Google Patents
Formulaciones en cápsulas, método de preparaciónInfo
- Publication number
- AR117219A1 AR117219A1 ARP190103505A ARP190103505A AR117219A1 AR 117219 A1 AR117219 A1 AR 117219A1 AR P190103505 A ARP190103505 A AR P190103505A AR P190103505 A ARP190103505 A AR P190103505A AR 117219 A1 AR117219 A1 AR 117219A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- solid solution
- solution capsule
- capsules
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000006104 solid solution Substances 0.000 abstract 5
- 239000007963 capsule composition Substances 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000002844 melting Methods 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000002736 nonionic surfactant Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 102000005590 Anaphylatoxin C5a Receptor Human genes 0.000 abstract 1
- 108010059426 Anaphylatoxin C5a Receptor Proteins 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 abstract 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 229940072106 hydroxystearate Drugs 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente provee formulaciones en cápsulas de solución sólida del Compuesto de fórmula (1) y métodos para preparar las mismas. En la presente también se proveen métodos para tratar individuos que padecen de, o son susceptibles a, una enfermedad o trastorno que implica la activación patológica de receptores de C5a al administrar una cantidad efectiva de una o más cápsulas de solución sólida que comprenden el Compuesto de fórmula (1). En la presente se proveen, además, cápsulas de dosis unitarias que comprenden ciertas cantidades del Compuesto de fórmula (1), y kits que comprenden una cápsula de solución sólida que comprende el Compuesto de fórmula (1). Reivindicación 1: Una formulación en cápsula de solución sólida que comprende el Compuesto de fórmula (1) como base libre, en su forma neutra o en forma de una sal farmacéuticamente aceptable y un vehículo que comprende al menos un agente tensioactivo no iónico que tiene un valor de equilibrio hidrófilo-lipófilo (HLB) de al menos 10, y al menos un solubilizante soluble en agua que tiene un punto de fusión igual o superior a 37ºC. Reivindicación 19: La cápsula de solución sólida de una cualquiera de las reivindicaciones 1 a 10, en donde dicho al menos un agente tensioactivo no iónico que tiene un valor de HLB de al menos 10 es macrogol-40-glicol hidroxiestearato y dicho al menos un solubilizante soluble en agua que tiene una temperatura de fusión igual o superior a 37ºC es PEG-4000.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862773848P | 2018-11-30 | 2018-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117219A1 true AR117219A1 (es) | 2021-07-21 |
Family
ID=70849818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103505A AR117219A1 (es) | 2018-11-30 | 2019-11-29 | Formulaciones en cápsulas, método de preparación |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US20200170957A1 (es) |
| EP (3) | EP4487915A3 (es) |
| JP (1) | JP7342124B2 (es) |
| KR (1) | KR102586747B1 (es) |
| CN (1) | CN113164403A (es) |
| AR (1) | AR117219A1 (es) |
| AU (1) | AU2019389031B2 (es) |
| BR (1) | BR112021010285A2 (es) |
| CA (1) | CA3120999C (es) |
| CL (1) | CL2021001389A1 (es) |
| CY (1) | CY1126079T1 (es) |
| DK (2) | DK4233850T3 (es) |
| ES (2) | ES2998858T3 (es) |
| FI (2) | FI3886820T3 (es) |
| HR (2) | HRP20241735T1 (es) |
| HU (2) | HUE069633T2 (es) |
| IL (1) | IL283450B2 (es) |
| LT (2) | LT4233850T (es) |
| MA (2) | MA54318B1 (es) |
| MD (2) | MD4233850T2 (es) |
| MX (1) | MX2021006242A (es) |
| NZ (1) | NZ776554A (es) |
| PL (2) | PL3886820T3 (es) |
| PT (2) | PT3886820T (es) |
| RS (2) | RS64250B1 (es) |
| SG (1) | SG11202105572UA (es) |
| SI (2) | SI4233850T1 (es) |
| SM (2) | SMT202400521T1 (es) |
| TW (1) | TWI827745B (es) |
| WO (1) | WO2020112961A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4233850T3 (da) | 2018-11-30 | 2025-01-02 | Chemocentryx Inc | Kapselformuleringer |
| BR112022007489A2 (pt) | 2019-11-08 | 2022-07-12 | Chemocentryx Inc | Forma amorfa de um receptor c5a de componente do complemento |
| CN116529241A (zh) * | 2020-10-28 | 2023-08-01 | 坎莫森特里克斯公司 | 治疗化脓性汗腺炎的方法 |
| CA3192880A1 (en) * | 2020-10-28 | 2022-05-05 | Chemocentryx, Inc. | Methods of treating hidradenitis suppurativa |
| KR20230124981A (ko) * | 2020-12-21 | 2023-08-28 | 케모센트릭스, 인크. | C5a 억제제를 사용한 c3 사구체병증의 치료 |
| CN119031903A (zh) * | 2022-05-19 | 2024-11-26 | 陶氏环球技术有限责任公司 | 基于peg的聚合物间复合物用于改善bcs ii类药物的增溶的用途 |
| WO2025203055A1 (en) * | 2024-03-26 | 2025-10-02 | Council Of Scientific And Industrial Research | Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038681A1 (es) | 2002-02-14 | 2005-01-26 | Solvay Pharm Bv | Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua |
| CA2587733A1 (en) * | 2004-11-24 | 2006-06-01 | Merck & Co., Inc. | Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| EP4015504A1 (en) | 2008-12-22 | 2022-06-22 | ChemoCentryx, Inc. | C5ar antagonists |
| US20110312973A1 (en) | 2010-03-10 | 2011-12-22 | Bernd Liepold | Solid compositions |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| US9034858B2 (en) * | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9074470B2 (en) | 2010-12-27 | 2015-07-07 | Seven Generations Energy Ltd. | Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources |
| EA037895B1 (ru) | 2014-02-05 | 2021-06-02 | Лек Фармасьютикалз Д.Д. | Твердые фармацевтические композиции антагонистов рецепторов андрогенов |
| CA3220371A1 (en) | 2014-09-29 | 2016-04-07 | Chemocentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| WO2017123716A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
| NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| CN111108118A (zh) | 2017-04-03 | 2020-05-05 | 因弗拉克斯有限责任公司 | 用C5a活性抑制剂治疗炎性疾病 |
| US20190144389A1 (en) | 2017-10-30 | 2019-05-16 | Chemocentryx, Inc. | Deuterated compounds as immunomodulators |
| EP4671767A2 (en) | 2017-10-31 | 2025-12-31 | ChemoCentryx, Inc. | URINARY SCD163 C5AR INHIBITOR REDUCTION |
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス，インコーポレイティド | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
| DK4233850T3 (da) | 2018-11-30 | 2025-01-02 | Chemocentryx Inc | Kapselformuleringer |
-
2019
- 2019-11-27 DK DK23160271.5T patent/DK4233850T3/da active
- 2019-11-27 LT LTEP23160271.5T patent/LT4233850T/lt unknown
- 2019-11-27 DK DK19889873.6T patent/DK3886820T3/da active
- 2019-11-27 SI SI201930868T patent/SI4233850T1/sl unknown
- 2019-11-27 MA MA54318A patent/MA54318B1/fr unknown
- 2019-11-27 PT PT198898736T patent/PT3886820T/pt unknown
- 2019-11-27 EP EP24196793.4A patent/EP4487915A3/en active Pending
- 2019-11-27 ES ES23160271T patent/ES2998858T3/es active Active
- 2019-11-27 HR HRP20241735TT patent/HRP20241735T1/hr unknown
- 2019-11-27 SM SM20240521T patent/SMT202400521T1/it unknown
- 2019-11-27 IL IL283450A patent/IL283450B2/en unknown
- 2019-11-27 PT PT231602715T patent/PT4233850T/pt unknown
- 2019-11-27 PL PL19889873.6T patent/PL3886820T3/pl unknown
- 2019-11-27 RS RS20230433A patent/RS64250B1/sr unknown
- 2019-11-27 MX MX2021006242A patent/MX2021006242A/es unknown
- 2019-11-27 SI SI201930524T patent/SI3886820T1/sl unknown
- 2019-11-27 RS RS20241401A patent/RS66362B1/sr unknown
- 2019-11-27 KR KR1020217019883A patent/KR102586747B1/ko active Active
- 2019-11-27 FI FIEP19889873.6T patent/FI3886820T3/fi active
- 2019-11-27 LT LTEPPCT/US2019/063547T patent/LT3886820T/lt unknown
- 2019-11-27 SM SM20230153T patent/SMT202300153T1/it unknown
- 2019-11-27 JP JP2021531035A patent/JP7342124B2/ja active Active
- 2019-11-27 HU HUE23160271A patent/HUE069633T2/hu unknown
- 2019-11-27 EP EP19889873.6A patent/EP3886820B8/en active Active
- 2019-11-27 CA CA3120999A patent/CA3120999C/en active Active
- 2019-11-27 FI FIEP23160271.5T patent/FI4233850T3/fi active
- 2019-11-27 ES ES19889873T patent/ES2943492T3/es active Active
- 2019-11-27 HU HUE19889873A patent/HUE062551T2/hu unknown
- 2019-11-27 US US16/697,523 patent/US20200170957A1/en not_active Abandoned
- 2019-11-27 MD MDE20231131T patent/MD4233850T2/ro unknown
- 2019-11-27 AU AU2019389031A patent/AU2019389031B2/en active Active
- 2019-11-27 WO PCT/US2019/063547 patent/WO2020112961A1/en not_active Ceased
- 2019-11-27 PL PL23160271.5T patent/PL4233850T3/pl unknown
- 2019-11-27 NZ NZ776554A patent/NZ776554A/en unknown
- 2019-11-27 MA MA62992A patent/MA62992B1/fr unknown
- 2019-11-27 EP EP23160271.5A patent/EP4233850B1/en active Active
- 2019-11-27 CN CN201980079276.4A patent/CN113164403A/zh active Pending
- 2019-11-27 SG SG11202105572UA patent/SG11202105572UA/en unknown
- 2019-11-27 MD MDE20210972T patent/MD3886820T2/ro unknown
- 2019-11-27 BR BR112021010285-0A patent/BR112021010285A2/pt not_active Application Discontinuation
- 2019-11-27 HR HRP20230551TT patent/HRP20230551T1/hr unknown
- 2019-11-29 TW TW108143799A patent/TWI827745B/zh active
- 2019-11-29 AR ARP190103505A patent/AR117219A1/es unknown
-
2021
- 2021-05-27 CL CL2021001389A patent/CL2021001389A1/es unknown
- 2021-12-08 US US17/545,878 patent/US11951214B2/en active Active
-
2023
- 2023-07-03 CY CY20231100309T patent/CY1126079T1/el unknown
-
2024
- 2024-02-09 US US18/437,368 patent/US20240299306A1/en not_active Abandoned
-
2025
- 2025-08-28 US US19/313,405 patent/US20250375385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117219A1 (es) | Formulaciones en cápsulas, método de preparación | |
| CL2019002167A1 (es) | Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.) | |
| MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
| TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| MX2017010220A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| PE20191650A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR128459A2 (es) | Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación | |
| JOP20180071A1 (ar) | استخدام مشتقات أمينو ألكيل بنزوثيازبين | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| CR20220018A (es) | Derivados de imidazol [4,5-c] piridina como agonistas de receptores tipo toll | |
| MX2016009063A (es) | Preparacion farmaceutica que contiene compuesto de acido piridilaminoacetico. | |
| CL2019001023A1 (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| PE20190347A1 (es) | Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant | |
| MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
| MX384072B (es) | Compuesto derivado de pirrolo-piridina, metodo para preparar el mismo y composicion farmaceutica que contiene el mismo como ingrediente activo para la prevencion o el tratamiento de enfermedades relacionadas con la proteina cinasa. | |
| BR112015027436A8 (pt) | composição tópica e veículo para administração de ingredientes farmaceuticamente ou cosmeticamente ativos | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| JP2015506922A5 (es) | ||
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| RU2018114922A (ru) | Лечение очаговой алопеции | |
| UY39466A (es) | Compuestos y composiciones para el tratamiento de la criptosporidiosis |